Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prexigebersen - Bio-Path Holdings

Next Previous
Drug Profile

Prexigebersen - Bio-Path Holdings

Alternative Names: BP 100-1-01; BP-100-1.01; BP-1001; BP1001-A; L-Grb-2; L-Grb-2 antisense; Liposomal Grb2 antisense oligonucleotide; Prexigebersen-A

Latest Information Update: 05 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Bio-Path Holdings; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action GRB2 adaptor protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase I/II Chronic myeloid leukaemia
  • Phase I Solid tumours
  • No development reported Breast cancer; Colorectal cancer; Head and neck cancer; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Thyroid cancer

Most Recent Events

  • 02 Apr 2024 Bio-Path Holdings plans to pursue US FDA Fast Track designation for the accelerated approval of Prexigebersen for Acute myeloid leukemia
  • 02 Apr 2024 Bio-Path Holdings announced plans to evaluate Prexigebersen for Obesity
  • 01 Aug 2023 Updated efficacy and safety data from the phase II trial in Acute myeloid leukemia (AML) released by Bio-Path Holdings
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top